Company Analysis
Sign in

Cue Biopharma, Inc. (CUE)

Nasdaq: CUE · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2015
Full chart Alerts Compare
Grade4.8
◀ Past 4.0● Present 4.0▶ Future 6.7
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

32 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Cue Biopharma, Inc.’s names, not what it holds today.

Patents granted
32
32 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 10 in 2024 and 7 in 2023
Applications published
110
19 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals28
Biotechnology4
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Cue Biopharma, Inc. its own name
named as the applicant on its applications, in US
0 granted
110 published
Cue Biopharma, Inc. its own name
US, as the owner printed on each patent
32 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 2, 202512,485,184Multimeric T-cell modulatory polypeptides and methods of use thereofPharmaceuticalsCue Biopharma, Inc.
Dec 2, 202512,485,183Multimeric T-cell modulatory polypeptides and methods of use thereofPharmaceuticalsCue Biopharma, Inc.
Sep 23, 202512,421,287T-cell modulatory multimeric polypeptides and methods of use thereofPharmaceuticalsCue Biopharma, Inc.
Mar 25, 202512,257,311Multimeric T-cell modulatory polypeptides and methods of use thereofPharmaceuticalsCue Biopharma, Inc.
Dec 31, 202412,180,258T-cell modulatory multimeric polypeptides and methods of use thereofPharmaceuticalsCue Biopharma, Inc.
Nov 26, 202412,152,061T-cell modulatory multimeric polypeptides and methods of use thereofPharmaceuticalsCue Biopharma, Inc.
Nov 19, 202412,145,973T-cell modulatory multimeric polypeptides and methods of use thereofPharmaceuticalsCue Biopharma, Inc.
Jul 9, 202412,029,782MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereofBiotechnologyCue Biopharma, Inc.
Jun 11, 202412,006,348T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereofPharmaceuticalsCue Biopharma, Inc.
May 28, 202411,993,641Methods for modulating an immune responsePharmaceuticalsCue Biopharma, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 11, 20252025/0376491T-Cell Modulatory Multimeric Polypeptides and Methods of Use ThereofBiotechnologyCue Biopharma, Inc.
Aug 28, 20252025/0270284MHC Class II Protein ConstructsBiotechnologyCue Biopharma, Inc.
Jul 31, 20252025/0243254Interleukin-2 Polypeptides, Fusion Polypeptides, and Methods of Use ThereofPharmaceuticalsCue Biopharma, Inc.
Jul 31, 20252025/0243253T-Cell Modulatory Multimeric Polypeptides and Methods of Use ThereofPharmaceuticalsCue Biopharma, Inc. · patent 12,421,287 granted from it
Jul 31, 20252025/0242005T-Cell Modulatory Multimeric Polypeptides and Methods of Use ThereofPharmaceuticalsCue Biopharma, Inc.
Jun 26, 20252025/0206794TGF-Beta PolypeptidesBiotechnologyCue Biopharma, Inc.
May 22, 20252025/0161355PROTEINS FOR MODULATING CELL THERAPY PRODUCTS AND METHODS OF USE THEREOFBiotechnologyCue Biopharma, Inc.
May 8, 20252025/0145685METHODS FOR MODULATING AN IMMUNE RESPONSEPharmaceuticalsCue Biopharma, Inc.
May 1, 20252025/0136660METHODS FOR MODULATING AN IMMUNE RESPONSEPharmaceuticalsCue Biopharma, Inc.
Apr 17, 20252025/0120996T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOFBiotechnologyCue Biopharma, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 25 · Biotechnology 19 · Medical technology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CUE · research, not advice